Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients
We analyzed serially collected serum samples from healthy adults who underwent BNT162b2 vaccination to elucidate the association between spike (S)-IgG antibody titers determined by ELISA using the WHO international standard (NIBSC code 20/136) and neutralizing antibody titers against three live SARS...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2105611 |
| _version_ | 1827806441801515008 |
|---|---|
| author | Yuki Higashimoto Kei Kozawa Hiroki Miura Yoshiki Kawamura Masaru Ihira Hiroyuki Hiramatsu Ryota Suzuki Kei Haga Reiko Takai-Todaka Akihito Sawada Kazuhiko Katayama Tetsushi Yoshikawa |
| author_facet | Yuki Higashimoto Kei Kozawa Hiroki Miura Yoshiki Kawamura Masaru Ihira Hiroyuki Hiramatsu Ryota Suzuki Kei Haga Reiko Takai-Todaka Akihito Sawada Kazuhiko Katayama Tetsushi Yoshikawa |
| author_sort | Yuki Higashimoto |
| collection | DOAJ |
| description | We analyzed serially collected serum samples from healthy adults who underwent BNT162b2 vaccination to elucidate the association between spike (S)-IgG antibody titers determined by ELISA using the WHO international standard (NIBSC code 20/136) and neutralizing antibody titers against three live SARS-CoV-2 variants. This study included 53 health care workers who received two doses of the BNT162b2 vaccine. S-IgG and nucleocapsid (N)-IgG antibody titers were measured by ELISA. Neutralizing (NT) antibody responses against three variants (Wuhan D614 G: KUH003, Alpha, and Delta) were evaluated before and after the first and second vaccination. N-IgG were not detected in any serum samples. S-IgG antibody titers remarkably increased after two BNT162b2 vaccine doses in all participants. S-IgG antibody titers were strongly correlated with NT titers against three variants of live viruses: KUH003 (r = 0.86), Alpha (r = 0.72), and Delta (r = 0.84). Serum samples from participants after one dose of BNT162b2 neutralized Alpha efficiently (median titer, 113.0), but median NT titers against KUH003 and Delta variants were lower, 57.0 and 28.0, respectively (p < .01). Two doses of the BNT162b2 vaccine elicited a strong immune response in this study. The second dose was required for induction of a strong booster effect. Serum collected from BNT162b2 vaccine recipients contained significantly lower neutralizing activity against Delta than that of against KUH003 (p < .0001) and Alpha (p < .0001). If a new variant emerges, live virus-based NT titers should be examined in serum obtained from vaccine recipients to evaluate vaccine efficacy for protection against infection. |
| first_indexed | 2024-03-11T21:41:12Z |
| format | Article |
| id | doaj.art-eadc5717727040f7951fccbb6d6d9c0f |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:12Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-eadc5717727040f7951fccbb6d6d9c0f2023-09-26T13:19:08ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.21056112105611Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipientsYuki Higashimoto0Kei Kozawa1Hiroki Miura2Yoshiki Kawamura3Masaru Ihira4Hiroyuki Hiramatsu5Ryota Suzuki6Kei Haga7Reiko Takai-Todaka8Akihito Sawada9Kazuhiko Katayama10Tetsushi Yoshikawa11Fujita Health University School of Medical SciencesFujita Health University School of MedicineFujita Health University School of MedicineFujita Health University School of MedicineFujita Health University School of Medical SciencesFujita Health University HospitalFujita Health University HospitalKitasato UniversityKitasato UniversityKitasato UniversityKitasato UniversityFujita Health University School of MedicineWe analyzed serially collected serum samples from healthy adults who underwent BNT162b2 vaccination to elucidate the association between spike (S)-IgG antibody titers determined by ELISA using the WHO international standard (NIBSC code 20/136) and neutralizing antibody titers against three live SARS-CoV-2 variants. This study included 53 health care workers who received two doses of the BNT162b2 vaccine. S-IgG and nucleocapsid (N)-IgG antibody titers were measured by ELISA. Neutralizing (NT) antibody responses against three variants (Wuhan D614 G: KUH003, Alpha, and Delta) were evaluated before and after the first and second vaccination. N-IgG were not detected in any serum samples. S-IgG antibody titers remarkably increased after two BNT162b2 vaccine doses in all participants. S-IgG antibody titers were strongly correlated with NT titers against three variants of live viruses: KUH003 (r = 0.86), Alpha (r = 0.72), and Delta (r = 0.84). Serum samples from participants after one dose of BNT162b2 neutralized Alpha efficiently (median titer, 113.0), but median NT titers against KUH003 and Delta variants were lower, 57.0 and 28.0, respectively (p < .01). Two doses of the BNT162b2 vaccine elicited a strong immune response in this study. The second dose was required for induction of a strong booster effect. Serum collected from BNT162b2 vaccine recipients contained significantly lower neutralizing activity against Delta than that of against KUH003 (p < .0001) and Alpha (p < .0001). If a new variant emerges, live virus-based NT titers should be examined in serum obtained from vaccine recipients to evaluate vaccine efficacy for protection against infection.http://dx.doi.org/10.1080/21645515.2022.2105611covid-19sars-cov-2elisaneutralizing antibody |
| spellingShingle | Yuki Higashimoto Kei Kozawa Hiroki Miura Yoshiki Kawamura Masaru Ihira Hiroyuki Hiramatsu Ryota Suzuki Kei Haga Reiko Takai-Todaka Akihito Sawada Kazuhiko Katayama Tetsushi Yoshikawa Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients Human Vaccines & Immunotherapeutics covid-19 sars-cov-2 elisa neutralizing antibody |
| title | Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients |
| title_full | Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients |
| title_fullStr | Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients |
| title_full_unstemmed | Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients |
| title_short | Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients |
| title_sort | correlation between anti s igg and neutralizing antibody titers against three live sars cov 2 variants in bnt162b2 vaccine recipients |
| topic | covid-19 sars-cov-2 elisa neutralizing antibody |
| url | http://dx.doi.org/10.1080/21645515.2022.2105611 |
| work_keys_str_mv | AT yukihigashimoto correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT keikozawa correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT hirokimiura correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT yoshikikawamura correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT masaruihira correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT hiroyukihiramatsu correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT ryotasuzuki correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT keihaga correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT reikotakaitodaka correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT akihitosawada correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT kazuhikokatayama correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients AT tetsushiyoshikawa correlationbetweenantisiggandneutralizingantibodytitersagainstthreelivesarscov2variantsinbnt162b2vaccinerecipients |